Heart Failure Clinical Trials

None

None

None

None

Acute Effects of Exogenous Ketone Ester Administration in Heart Failure

Please see section 1 of the full protocol

Skeletal Muscle Perfusion and Mitochondrial Function in Heart Failure with Preserved Ejection Fraction

The study is being conducted to understand why the skeletal muscle of patients with Heart Failure with Preserved Ejection Fraction (HFpEF) does not work as well as the muscle of individuals without heart failure. This study seeks to understand whether the problem is with blood and oxygen delivery to the …

EMPACT-MI: A streamlined multicentre randomised parallel group double-blind placebo-controlled superiority trial to evaluate the effect of Empagliflozin on hospitalisation for heart failure and mortality in patients with aCuTe Myocardial Infarction

TBD

AN EXPLORATORY OPEN-LABEL PROOF-OF-CONCEPT PHASE 2A STUDY OF MAVACAMTEN (MYK-461) IN PARTICIPANTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF) AND CHRONIC ELEVATION OF CARDIAC TROPONIN I AND/OR NT-PROBNP

This is a multicenter, exploratory, open-label study to explore the efficacy and/or pharmacodynamic effect, PK, safety, and tolerability of mavacamten in approximately 35 ambulatory participants with symptomatic HFpEF and elevated cTnI and/or elevated NT-proBNP as defined in inclusion/exclusion criteria. The study will include an up to 7-week screening period (with …

Matching Perfusion and Metabolic Activity in HFpEF

This study will test whether Potassium Nitrate (KNO3), with and without Propionyl-L-Carnitine (PLC) and Nicotinamide Riboside (NR), improves submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in participants with Heart Failure with Preserved Ejection Fraction (HFpEF). This study will also test whether the response to supplemental oxygen …

A Prospective Randomised Trial of Early LV Venting Using Impella CP for Recovery in patients with cardiogenic managed with VA ECMO (REVERSE)

Veno-arterial (VA) extra-corporeal membrane oxygenation (ECMO) is indicated as a haemodynamic rescue strategy in decompensated acute or chronic heart failure presenting as cardiogenic shock. VA ECMO has a number of effects on the circulation including (i) perfusing end-organs, (ii) ventricular unloading, and (iii) improved coronary perfusion.